Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Increased expression of excision repair cross-complementing 1 (ERCC1) in mCRC patients could be related to their response to Oxaliplatin based chemotherapy. We evaluated ERCC1 mRNA expression levels in primary bowel and liver metastases of 51 patients, and correlated with pathologic parameters and clinical outcomes. A significant negative correlation was detected between primary tumor ERCC1 and both the extent of clear surgical margins (P = 0.0011) and the percent of liver metastasis necrosis (P = 0.0167). No relationship was observed between ERCC1 expression and survival. Further study is needed to assess the promising role of ERCC1 expression as a predictive marker benefiting subgroups for Oxaliplatin.

Original publication




Journal article


Cancer Invest

Publication Date





89 - 97


ERCC1, Metastatic colorectal cancer, Oxaliplatin, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, DNA-Binding Proteins, Endonucleases, Female, Humans, Liver, Liver Neoplasms, Male, Middle Aged, Neoadjuvant Therapy, Organoplatinum Compounds, Oxaliplatin